Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Swiss study reveals Real-World impact of MS drug kesimpta

NCT ID NCT05285904

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 107 adults in Switzerland with relapsing multiple sclerosis who were already taking Kesimpta (ofatumumab) as part of their routine care. Researchers tracked how many patients had no signs of disease activity, including relapses, new brain lesions, or worsening disability. The goal was to see how well the drug works outside of a controlled clinical trial setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

107 people

The number who actually took part.

Started

May 2022

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include male and female patients (aged ≥ 18 years) with a documented diagnosis of RMS and treated for at least 3 months with Ofatumumab

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent must be obtained before participating in the study. 2. Diagnosis of RMS per McDonald Criteria (2017) occurred within 3 years prior to initiation of Ofatumumab. 3. Adult patients who have been on treatment with Ofatumumab for at least 3 months, but not longer than 12 months prior to inclusion in the study. 4. Ofatumumab treatment in line with the Swiss Kesimpta® label (i.e. adult patients with active, relapsing forms of MS) 5. Patient is willing and able to complete patient diary during course of the study, as well as to complete PRO questionnaires. Exclusion Criteria: 1. Use of investigational drugs during the study, OR between Ofatumumab initiation and inclusion into the study, OR within 3 months before Ofatumumab initiation, OR within 5 half-lives of investigational drug before Ofatumumab initiation, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer. 2. Subjects who are not able to provide consent due to incapable judgement

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • Novartis Investigative Site

    Baden, Canton of Aargau, 5405, Switzerland

  • Novartis Investigative Site

    Lucerne, Canton of Lucerne, 6004, Switzerland

  • Novartis Investigative Site

    Lucerne, Canton of Lucerne, 6006, Switzerland

  • Novartis Investigative Site

    Sargans, Canton of St. Gallen, 7320, Switzerland

  • Novartis Investigative Site

    Gland, Canton of Vaud, 1196, Switzerland

  • Novartis Investigative Site

    Zurich, Canton of Zurich, 8006, Switzerland

  • Novartis Investigative Site

    Zurich, CHE, 8001, Switzerland

  • Novartis Investigative Site

    Basel, 4001, Switzerland

  • Novartis Investigative Site

    Bern, 3010, Switzerland

  • Novartis Investigative Site

    Lausanne, 1011, Switzerland

  • Novartis Investigative Site

    Lucerne, 6000, Switzerland

  • Novartis Investigative Site

    Lugano, 6900, Switzerland

  • Novartis Investigative Site

    Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.